The Mesothelioma Treatment Landscape in 2026

The mesothelioma treatment landscape has changed more in the past six years than in the previous thirty. The 2020 FDA approval of nivolumab plus ipilimumab ended 16 years without a new first-line option. The 2026 five-year update to the CheckMate-743 trial confirmed the durability of that benefit. A new generation of bispecific antibodies, cell therapies, and targeted drugs is now moving through Phase 2 and Phase 3 trials.

This is the full picture of what is approved, what is promising, and what is still coming.

Approved First-Line Treatments

Nivolumab Plus Ipilimumab

The CheckMate-743 trial changed the standard of care when initial results were published in 2021. The 2026 update, published in the Journal of Clinical Oncology at a median follow-up of 66.8 months, confirmed and extended those findings. At five years:

• 14% of patients on the immunotherapy combination were still alive, compared to 6% on chemotherapy
• 17% of patients who initially responded to immunotherapy maintained their response at five years; 0% of chemotherapy responders did
• In non-epithelioid disease, where chemotherapy has historically been least effective, 5-year survival was 12% on immunotherapy versus 1% on chemotherapy

The trial also identified a potential biomarker. Patients with high baseline levels of monocytic myeloid-derived suppressor cells (M-MDSCs) had worse outcomes overall, but still benefited more from immunotherapy than from chemotherapy within that subgroup.

Chemotherapy

Cisplatin or carboplatin combined with pemetrexed was approved in 2004 and remains the standard alternative for patients who cannot tolerate immunotherapy or who are ineligible for clinical trials. Response rates are around 41%. Median survival is 14 months. The regimen is also used in combination with newer drugs in several Phase 2 trials.

Surgical Treatment

Surgery remains the most effective treatment for mesothelioma in patients who qualify. The MARS 2 trial, published in 2024, challenged the routine use of extrapleural pneumonectomy (EPP) by showing higher mortality without a survival benefit, and most centers have shifted toward pleurectomy/decortication (P/D) for pleural disease.

For peritoneal mesothelioma, cytoreductive surgery combined with heated intraperitoneal chemotherapy (HIPEC) produces the best long-term outcomes of any mesothelioma treatment. Five-year survival rates at high-volume centers reach 47% to 52%, nearly five times the overall average. The approach requires specialized expertise and is offered at approximately 60 centers in the United States.

Investigational and Emerging Treatments

BNT327 (PM8002)

The most watched drug in the mesothelioma pipeline is BNT327, a bispecific antibody that simultaneously blocks PD-L1 (an immune checkpoint) and VEGF-A (a protein tumors use to grow blood vessels). Phase 2 data in 31 previously untreated patients showed:

• 52% overall response rate (vs 40% for CheckMate-743)
• 90% disease control rate (vs 77% for CheckMate-743)
• 16.6-month median progression-free survival (vs 6.8 months for CheckMate-743)
• 75% response rate and 100% disease control rate in peritoneal patients at 20 months follow-up

A 2026 preclinical study helped explain why dual-mechanism drugs like BNT327 may be particularly effective in peritoneal disease, where single-agent checkpoint therapy has historically performed poorly.

The drug is not yet FDA approved. Phase 2 trials are running primarily in China, and BioNTech has not announced a Phase 3 timeline for mesothelioma. Patients interested in BNT327 should discuss international trial eligibility with their oncologist.

Durvalumab

Durvalumab, a PD-L1 inhibitor, showed promising Phase 2 results in the DREAM and PrE0505 trials, with median overall survival of 21 months when combined with standard chemotherapy. The Phase 3 DREAM3R trial is ongoing. If the results replicate, durvalumab plus chemotherapy could join nivolumab-ipilimumab as a standard first-line option.

ADI-PEG20

ADI-PEG20 takes a different approach. About 50% of mesothelioma tumors cannot make their own arginine, an amino acid essential for growth. ADI-PEG20 depletes arginine from the bloodstream, effectively starving these tumors. The Phase 3 ATOMIC-Meso trial reported improved progression-free survival when ADI-PEG20 was added to standard chemotherapy.

VT3989 and TEAD Inhibitors

The YAP/TEAD signaling pathway is hyperactive in approximately half of mesothelioma cases, driven by loss of the NF2 tumor suppressor gene. VT3989 is a first-in-class TEAD inhibitor that blocks this pathway. Early Phase 1 data showed approximately 20% response rates in heavily pretreated patients. The drug is oral and well-tolerated, making it a potential option for later-line treatment.

TTFields (Optune Lua)

Tumor-treating fields, delivered by the Optune Lua device, is an FDA-approved treatment that uses alternating electric fields to disrupt cancer cell division. The device is worn on the chest and used alongside standard chemotherapy. It adds to existing regimens rather than replacing them.

CAR-T and Cell Therapies

Multiple Phase 1 trials are testing engineered T cells against mesothelin, a protein expressed on nearly all mesothelioma cells. Results have been mixed, with responses in some patients balanced against significant toxicity concerns. The approach remains investigational but active.

Treatment by Subtype

Treatment decisions depend heavily on the type of mesothelioma and the patient’s overall health.

Epithelioid pleural mesothelioma has the best prognosis and the most treatment options. First-line nivolumab-ipilimumab is standard. Surgery is considered for early-stage disease. Multimodal approaches combining surgery, chemotherapy, and sometimes radiation are used at specialized centers.

Non-epithelioid pleural mesothelioma (sarcomatoid or biphasic) responds less well to chemotherapy but shows a dramatically larger immunotherapy benefit. The 2026 CheckMate-743 update reported 12% 5-year survival on immunotherapy versus 1% on chemotherapy in this subgroup, making the choice especially clear.

Peritoneal mesothelioma is treated primarily with cytoreductive surgery plus HIPEC when operable. For unresectable disease, clinical trial enrollment is often the best path to effective treatment. No immunotherapy is specifically approved for peritoneal disease.

Recurrent or refractory mesothelioma has fewer established options. Second-line nivolumab showed a survival benefit in the CONFIRM trial. Clinical trials of newer agents are the main path forward.

What Is Still Missing

Despite the progress, gaps remain.

Response rates to first-line immunotherapy still plateau between 40% and 55%. More than half of patients do not respond to the best available treatment, and durable long-term responses are the exception rather than the rule.

No immunotherapy has been specifically approved for peritoneal mesothelioma. The major Phase 3 trials (CheckMate-743, DREAM, PrE0505, DREAM3R) have excluded peritoneal patients, leaving them dependent on off-label use or clinical trial enrollment.

Biomarkers that reliably predict response to therapy have not emerged. PD-L1, commonly used in other cancers, shows weak correlation with outcomes in mesothelioma. The CheckMate-743 M-MDSC signal is promising but needs prospective validation.

Access to clinical trials is uneven. Many patients are treated outside of mesothelioma centers and never learn about investigational options that might fit their cases. States with high case volumes, like Illinois (670 documented exposure sites), Texas, and Pennsylvania, have the most active trial sites.

The Next Twelve Months

Three near-term developments are worth watching:

DREAM3R Phase 3 results. If durvalumab plus chemotherapy replicates its Phase 2 survival benefit, the FDA could approve a second first-line immunotherapy regimen, giving patients a genuine choice.

BNT327 Phase 3 plans. BioNTech has not committed to a mesothelioma Phase 3 trial, but the Phase 2 data are strong enough that additional development is likely. Peritoneal patients in particular have reason to watch.

ADAURA-mesothelioma and similar adjuvant trials. Several trials are testing immunotherapy after surgery for resectable disease. If they show benefit, the treatment paradigm could shift from “systemic therapy for unresectable disease” to “systemic therapy after surgery for all eligible patients.”